A5077529566- SARS-CoV-2 and COVID-19 Research
- Animal Virus Infections Studies
- Virus-based gene therapy research
- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- Monoclonal and Polyclonal Antibodies Research
- SARS-CoV-2 detection and testing
- Cancer Immunotherapy and Biomarkers
- COVID-19 Clinical Research Studies
- Viral gastroenteritis research and epidemiology
- Viral Infections and Outbreaks Research
- Virology and Viral Diseases
- RNA Interference and Gene Delivery
- Herpesvirus Infections and Treatments
- Bacillus and Francisella bacterial research
- vaccines and immunoinformatics approaches
- Viral Infectious Diseases and Gene Expression in Insects
- Viral Infections and Immunology Research
- Cancer Research and Treatments
- Vaccine Coverage and Hesitancy
- Toxin Mechanisms and Immunotoxins
- Bacteriophages and microbial interactions
- Radiopharmaceutical Chemistry and Applications
- Glycosylation and Glycoproteins Research
- Orthopaedic implants and arthroplasty
BioNTech (Germany)
2020-2025
BioNTech (United States)
2021-2023
The University of Texas Medical Branch at Galveston
2021
Institut de Recherche Vaccinale
2021
Paul Ehrlich Institut
2014-2019
Georg Speyer Haus
2011-2014
Innsbruck Medical University
2011
Recently, a new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lineage called B.1.1.7 (variant of concern: VOC 202012/01), which is reported to spread more efficiently and faster than other strains, emerged in the United Kingdom. This variant has an unusually large number mutations, with 10 amino acid changes spike (S) protein, raising concerns that its recognition by neutralizing antibodies may be affected. In this study, we tested SARS-CoV-2-S pseudoviruses bearing either...
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is continuing to evolve around the world, generating new variants that are of concern on basis their potential for altered transmissibility, pathogenicity, and coverage by vaccines therapeutic agents1-5. Here we show serum samples taken from twenty human volunteers, two or four weeks after second dose BNT162b2 vaccine, neutralize engineered SARS-CoV-2 with a USA-WA1/2020 genetic background (a virus strain isolated in January 2020)...
The globally circulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concern Omicron (B.1.1.529) has a large number mutations, especially in the spike protein, indicating that recognition by neutralizing antibodies may be compromised. We tested Wuhan (Wuhan-Hu-1 reference strain), Beta (B.1.351), Delta (B.1.617.2), or pseudoviruses with sera 51 participants who received two three doses messenger RNA (mRNA)-based COVID-19 vaccine BNT162b2. After doses,...
Omicron is the evolutionarily most distinct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concern (VOC) to date. We report that BA.1 breakthrough infection in BNT162b2-vaccinated individuals resulted strong neutralizing activity against BA.1, BA.2, and previous SARS-CoV-2 VOCs but not sublineages BA.4 BA.5. induced a robust recall response, primarily expanding memory B (B
BNT162b2, a lipid nanoparticle (LNP) formulated nucleoside-modified messenger RNA (mRNA) encoding the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S) stabilized in prefusion conformation, has demonstrated 95% efficacy to prevent disease 2019 (COVID-19). Recently, we reported preliminary BNT162b2 safety and antibody response data from an ongoing placebo-controlled, observer-blinded phase 1/2 vaccine trial 1 . We present here T cell responses second,...
Abstract Checkpoint inhibitors (CPI) have revolutionized the treatment paradigm for advanced solid tumors; however, there remains an opportunity to improve response rates and outcomes. In preclinical models, 4-1BB costimulation synergizes with CPIs targeting programmed cell death protein 1 (PD-1)/programmed ligand (PD-L1) axis by activating cytotoxic T-cell–mediated antitumor immunity. DuoBody-PD-L1×4-1BB (GEN1046) is investigational, first-in-class bispecific immunotherapy agent designed...
Abstract The newly emerged Omicron SARS-CoV-2 has several distinct sublineages including BA.1, BA.2, and BA.3. BA.1 accounts for the initial surge is being replaced by whereas BA.3 at a low prevalence this time. Here we report neutralization of BNT162b2-vaccinated sera (collected 1 month after dose 3) against three sublineages. To facilitate testing, have engineered complete or spike into an mNeonGreen USA-WA1/2020 SRAS-CoV-2. All neutralize USA-WA1/2020, BA.1-, BA.2-, BA.3-spike SARS-CoV-2s...
Abstract To contain the coronavirus disease 2019 (COVID-19) pandemic, a safe and effective vaccine against new severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is urgently needed in quantities sufficient to immunise large populations. In this study, we report design, preclinical development, immunogenicity anti-viral protective effect rhesus macaques of BNT162b2 candidate. contains an LNP-formulated nucleoside-modified mRNA that encodes spike glycoprotein captured its prefusion...
As cancer treatment tools, oncolytic viruses (OV) have yet to realize what some see as their ultimate clinical potential. In this study, we engineered a chimeric vesicular stomatitis virus (VSV) that is devoid of its natural neurotoxicity while retaining potent activity. The envelope glycoprotein (G) VSV was replaced with variant the lymphocytic choriomeningitis (LCMV-GP), creating replicating therapeutic, rVSV(GP), benign in normal brain but can effectively eliminate multiple preclinical...
We describe receptor-targeted adeno-associated viral (AAV) vectors that allow genetic modification of rare cell types ex vivo and in while showing no detectable off-targeting. Displaying designed ankyrin repeat proteins (DARPins) on the capsid carefully depleting DARPin-deficient particles, AAV were made specific for Her2/neu, EpCAM or CD4. A single intravenous administration vector targeted to tumour antigen Her2/neu was sufficient track 75% all sites extend survival longer than cytostatic...
Abstract Recently, a new SARS-CoV-2 lineage called B.1.1.7 has emerged in the United Kingdom that was reported to spread more efficiently than other strains. This variant an unusually large number of mutations with 10 amino acid changes spike protein, raising concerns its recognition by neutralizing antibodies may be affected. Here, we investigated SARS-CoV-2-S pseudoviruses bearing either Wuhan reference strain or protein sera 16 participants previously trial mRNA-based COVID-19 vaccine...
BNT162b2-vaccinated individuals after Omicron BA.1 breakthrough infection have strong serum-neutralizing activity against BA.1, BA.2, and previous SARS-CoV-2 variants of concern (VOCs) yet less the highly contagious sublineages BA.4 BA.5 that displaced variants. Because latter are derived from we characterized COVID-19 mRNA vaccine triple-immunized who experienced BA.2 infection. We demonstrate sera these broadly neutralizing VOCs all tested sublineages, including BA.2-derived BA.2.12.1...
Abstract The BNT162b2 bivalent BA.4/5 COVID-19 vaccine has been authorized to mitigate due current Omicron and potentially future variants. New sublineages of SARS-CoV-2 continue emerge have acquired additional mutations, particularly in the spike protein, that may lead improved viral fitness immune evasion. present study characterized neutralization activities against new BA.4.6, BA.2.75.2, BQ.1.1, XBB.1 after a 4 th dose (following three doses BNT162b2) either original monovalent or...
Distinct SARS-CoV-2 Omicron sublineages have evolved showing increased fitness and immune evasion than the original variant BA.1. Here, we report neutralization activity of sera from BNT162b2 vaccinated individuals or unimmunized BA.1-infected against "Deltacron" (XD). post-dose 3 neutralized USA-WA1/2020, BA.1-, BA.2-, BA.2.12.1-, BA.3-, BA.4/5-, XD-spike SARS-CoV-2s with geometric mean titres (GMTs) 1335, 393, 298, 315, 216, 103, 301, respectively; thus, BA.4/5 spike showed highest...
The ongoing COVID-19 pandemic is leading to the discovery of hundreds novel SARS-CoV-2 variants daily. While most do not impact course pandemic, some pose an increased risk when acquired mutations allow better evasion antibody neutralisation or transmissibility. Early detection such high-risk (HRVs) paramount for proper management pandemic. However, experimental assays determine immune and transmissibility characteristics new are resource-intensive time-consuming, potentially delays in...